𝔖 Bobbio Scriptorium
✦   LIBER   ✦

New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity

✍ Scribed by TOTH, KATALIN ;KOVACS, MAGDOLNA ;ZARANDI, MARTA ;HALMOS, GABOR ;GROOT, KATE ;NAGY, ATTILA ;KELE, ZOLTAN ;SCHALLY, ANDREW V.

Book ID
110893658
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
769 KB
Volume
51
Category
Article
ISSN
1397-002X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Inhibition of PC-3 human prostate cancer
Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity
✍ Artur Plonowski; Jozsef L. Varga; Andrew V. Schally; Magdalena Krupa; Kate Groot πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 202 KB

## Abstract Vasoactive intestinal peptide (VIP) stimulates the proliferation and invasiveness of malignant prostatic cells. Receptors for VIP and the closely related growth hormone‐releasing hormone (GH‐RH) show considerable homology and are found in prostatic and other carcinomas. Among various an

Inhibition of the growth of caki-I human
Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II
✍ Andreas Jungwirth; Andrew V. Schally; Gabor Halmos; Kate Groot; Karoly Szepeshaz πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 2 views

## Background: Metastatic or recurrent renal cell carcinoma (rcc) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. no uniformly effective therapeutic agents are available for the management of patients with rcc. hormones and growth factors may play a rol